Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. director, President and CEO K. Charles Janac reported an insider transaction involving a bona fide gift of common stock by an entity he manages. Bayview Legacy, LLC, for which he serves as manager, made a gift transfer of 50,000 shares of Common Stock at a stated price of $0.00 per share. After this gift, Bayview Legacy, LLC is shown as beneficially owning 8,999,071 shares of Common Stock, over which Janac is deemed to have voting and dispositive power.
The filing also lists additional holdings as of the same date: 196,729 shares of Common Stock held directly by Janac and 56,252 shares held indirectly through the Charles and Lydia Janac Trust, for which he serves as trustee. The reported transaction is a non-market, non-cash gift rather than an open-market purchase or sale, so it primarily reflects personal or estate-planning activity rather than a change in market view.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported a bona fide gift of 50,000 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share. This is a non-market transfer classified as a gift rather than a sale.
After the transaction, Bayview Legacy, LLC indirectly holds 8,999,071 Arteris shares. Footnotes state that K. Charles Janac controls Bayview Legacy, LLC as its manager and is deemed to have voting and dispositive power over these shares.
Arteris, Inc. VP and Chief Financial Officer Nicholas B. Hawkins reported an exercise-and-sell sequence in company stock. On May 15, 2026, he exercised stock options covering 213,021 shares of common stock at exercise prices of $0.56 and $9.28 per share.
On the same date, he sold 221,035 shares of common stock in open-market transactions at weighted average prices ranging from about $32.18 to $34.65 per share, according to the footnotes. After these trades, he continues to hold more than 100,000 shares directly.
AIP: Form 144 reporting proposed dispositions
Broker-dealer Morgan Stanley Smith Barney LLC submitted a Form 144 relating to AIP securities, listing a restricted stock vesting of 8,014 shares dated 04/01/2026 and exercises tied to 15,625 shares and 197,396 shares dated 05/15/2026. The filing also reports a sale by Nicholas Hawkins of 4,870 shares on 04/02/2026 for $85,969.13.
Arteris, Inc. director Antonio J. Viana reported open-market sales of a total of 40,000 shares of common stock, primarily through the Viana Family Trust. The trust sold 15,538 shares at a weighted average price of $34.0595, 4,462 shares at $35.3534, and 20,000 shares at $38.00.
Following these transactions, the Viana Family Trust held 64,620 shares indirectly, while Viana also held 20,840 shares directly. The filing states that the sales were made under a Rule 10b5-1 trading plan adopted on June 10, 2025, and notes that some shares were sold in multiple trades at prices ranging from $34.00 to $35.43.
AIP notice of proposed sale: a filer submitted a Form 144 disclosing proposed sale of 40,839 shares of Common Stock, with the filing date 05/14/2026. The excerpt also lists four prior 10b5-1 transactions: 20,000 shares on 04/17/2026, 20,000 on 04/24/2026, 20,000 on 05/05/2026, and 20,000 on 05/13/2026, each showing aggregate values in the excerpt.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice disclosing planned resale of 20,000 shares of Common Stock on behalf of a holder that previously exercised stock options on 01/28/2021. The excerpt also lists three recent 10b5-1 dispositions by the VIANA FAMILY TRUST: 04/17/2026 ($442,168, 20,000 shares), 04/24/2026 ($522,234, 20,000 shares), and 05/05/2026 ($601,464, 20,000 shares).
Arteris, Inc. director, President and CEO K. Charles Janac reported an indirect open-market sale of 70,000 shares of common stock at a weighted average price of $31.1998 per share through Bayview Legacy, LLC. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
Following the sale, Bayview Legacy, LLC held 9,049,071 shares of Arteris common stock. Janac also reported ownership of 196,729 shares held directly and 56,252 shares held indirectly through the Charles and Lydia Janac Trust, for which he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported an open-market sale of 70,000 shares of common stock on May 8, 2026 at a weighted average price of $31.1998 per share. The trades occurred at prices ranging from $29.19 to $32.07 per share.
After this transaction, Bayview Legacy, LLC held 9,049,071 shares of Arteris common stock indirectly. The sale was executed under a Rule 10b5-1 trading plan adopted by K. Charles Janac, who manages Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares.
Arteris, Inc. reported Q1 2026 results showing higher revenue but continued losses while integrating its Cycuity acquisition. Revenue rose to $22.9 million from $16.5 million a year earlier, led by licensing, support and maintenance and stronger variable royalties.
The company recorded a net loss of $8.0 million, or $0.17 per share, roughly in line with the prior-year loss. Operating cash flow swung to an outflow of $7.1 million, and cash and cash equivalents declined to $11.7 million, partly reflecting deal-related spending.
Arteris closed the $43.1 million Cycuity transaction, adding $18.1 million of intangible assets and increasing goodwill to $35.2 million. Annual Contract Value reached $84.9 million, with ACV plus royalties at $92.8 million and Remaining Performance Obligations at $118.3 million, indicating a growing base of contracted future revenue.